No registrations found.
ID
Source
Brief title
Health condition
Inflammatory bowel disease, IBD, Crohn's disease, Ulcerative colitis
Sponsors and support
Intervention
Outcome measures
Primary outcome
Agreement between IBDocTM result and the Quantum Blue result.
Secondary outcome
Agreement between IBDocTM at home and the result performed in the lab with the same extraction solution.
Study design
12 months
Intervention
In this study we want to compare the established Quantum Blue® method for measuring calprotectin with the new IBDocTM home-monitoring method. We wish to see whether they agree sufficiently for the new to replace the old.
Beatrix Children's Hospital<br>
Dept. Pediatric Gastroenterology<br>
Hanzeplein 1
P.F. Rheenen, van
Groningen 9713 GZ
The Netherlands
+31 (0)50 3614151
p.f.van.rheenen@umcg.nl
Beatrix Children's Hospital<br>
Dept. Pediatric Gastroenterology<br>
Hanzeplein 1
P.F. Rheenen, van
Groningen 9713 GZ
The Netherlands
+31 (0)50 3614151
p.f.van.rheenen@umcg.nl
Inclusion criteria
Eligible patients are those aged 12 to 19 years, with IBD diagnosed (according to the Porto criteria) more than 6 months before enrolment, who have a smartphone with access to internet, knowledge of the Dutch language, and an adult caregiver who is willing to actively support participation.
Exclusion criteria
Patients will be excluded from the study when they have an ileostomy (as calprotectin cut-offs are not validated for small bowel feces), or when they are taking medication that may influence stool calprotectin levels (NSAIDs).
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL4987 |
| NTR-old | NTR5133 |
| Other | MEtc UMCG : 2014.466. |